Advanced liver fibrosis can be assessed via APRI (aspartate transaminase (AST) to platelet ratio index), AST/alanine transaminase (ALT) ratio, or FIB-4 (fibrosis-4 index), and the risk of developing HCC by using aMAP (age-male-ALBI (albumin–bilirubin)-platelets) score. This evidence concerns the gene ALB and hepatocellular carcinoma.